Literature DB >> 15249849

Early-onset Alzheimer disease: when is genetic testing appropriate?

Jill S Goldman1, Craig E Hou.   

Abstract

Alzheimer disease (AD) is a neurodegenerative disease that is currently not preventable or curable. Early-onset AD can be due to mutations in several autosomal dominant genes. Clinical testing is available for presenilin 1 (PS1), which is the most common of these genes. However, many practical and ethical issues must be considered before ordering this test for patients with early-onset AD. In this paper, we present a case that demonstrates the complexities of genetic testing for early-onset AD.

Entities:  

Keywords:  Genetics and Reproduction

Mesh:

Substances:

Year:  2004        PMID: 15249849     DOI: 10.1097/01.wad.0000126616.77653.71

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  4 in total

1.  Ethical issues in diagnosing and treating Alzheimer disease.

Authors:  Edmund G Howe
Journal:  Psychiatry (Edgmont)       Date:  2006-05

2.  Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention.

Authors:  José M Ordovas
Journal:  Am J Clin Nutr       Date:  2009-04-01       Impact factor: 7.045

3.  Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine.

Authors:  Sandjar Djalalov; Jean Yong; Jaclyn Beca; Sandra Black; Gustavo Saposnik; Zahra Musa; Katherine Siminovitch; Myla Moretti; Jeffrey S Hoch
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

4.  Ethical Implications of Alzheimer's Disease Prediction in Asymptomatic Individuals through Artificial Intelligence.

Authors:  Frank Ursin; Cristian Timmermann; Florian Steger
Journal:  Diagnostics (Basel)       Date:  2021-03-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.